Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial - Lin, Yu-Hao; Zhang, Zhi-Jun; Zhong, Jin-Qing; Wang, Zhi-Yi; Peng, Yi-Ting; Lin, Yan-Mei; Zhang, Huo-Ping; Tian, Jian-Qing (PloS one, 2024)
Keywords: Active control; Adult; Aged; Agonists; Antidiabetics; Benzhydryl Compounds - adverse effects; Benzhydryl Compounds - therapeutic use; Blood Glucose - metabolism; Blood sugar; Body mass index; Bone turnover; C-reactive protein; Clinical trials; Comorbid patients; Dapagliflozin; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes therapy; Double-Blind Method; Drug therapy; Drug Therapy, Combination; Effectiveness; Enzymes; Exenatide; Family medical history; Fatty acids; Fatty liver; Female; Ferritin; Fibrosis; GLP-1 receptor agonists; Glucagon; Glucagon-Like Peptides - therapeutic use; Glucose; Glucosides - adverse effects; Glucosides - therapeutic use; Health services; Hemoglobin; Hepatitis; Humans; Hyperglycemia; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Informed consent; Inhibitors; Insulin; Insulin resistance; Lipids; Liver; Liver cirrhosis; Liver diseases; Male; Medical research; Medicine, Experimental; Metabolism; Middle Aged; Non-alcoholic Fatty Liver Disease - complications; Non-alcoholic Fatty Liver Disease - drug therapy; Patients; Peptides; Physiological aspects; Protein turnover; Randomized Controlled Trials as Topic; Receptors; Renal function; Sodium; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Synergistic effect; Treatment Outcome; Type 2 diabetes; China